Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?

DOI record: { "DOI": "10.1016/j.jiph.2024.102512", "ISSN": [ "1876-0341" ], "URL": "http://dx.doi.org/10.1016/j.jiph.2024.102512", "alternative-id": [ "S1876034124002466" ], "article-number": "102512", "assertion": [ { "label": "This article is maintained by", "name": "publisher", "value": "Elsevier" }, { "label": "Article Title", "name": "articletitle", "value": "Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?" }, { "label": "Journal Title", "name": "journaltitle", "value": "Journal of Infection and Public Health" }, { "label": "CrossRef DOI link to publisher maintained version", "name": "articlelink", "value": "https://doi.org/10.1016/j.jiph.2024.102512" }, { "label": "Content Type", "name": "content_type", "value": "simple-article" }, { "label": "Copyright", "name": "copyright", "value": "© 2024 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences." } ], "author": [ { "affiliation": [], "family": "Bang", "given": "Line Lundegaard", "sequence": "first" }, { "affiliation": [], "family": "Madsen", "given": "Lone Wulff", "sequence": "additional" }, { "affiliation": [], "family": "Pedersen", "given": "Rune Micha", "sequence": "additional" }, { "affiliation": [], "family": "Nilsson", "given": "Anna Christine", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-2189-9823", "affiliation": [], "authenticated-orcid": false, "family": "Johansen", "given": "Isik Somuncu", "sequence": "additional" }, { "affiliation": [], "family": "Andersen", "given": "Thomas Emil", "sequence": "additional" } ], "container-title": "Journal of Infection and Public Health", "container-title-short": "Journal of Infection and Public Health", "content-domain": { "crossmark-restriction": true, "domain": [ "clinicalkey.fr", "clinicalkey.jp", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.com", "elsevier.com", "sciencedirect.com" ] }, "created": { "date-parts": [ [ 2024, 8, 7 ] ], "date-time": "2024-08-07T02:24:28Z", "timestamp": 1722997468000 }, "deposited": { "date-parts": [ [ 2024, 8, 12 ] ], "date-time": "2024-08-12T19:33:58Z", "timestamp": 1723491238000 }, "funder": [ { "DOI": "10.13039/501100024075", "doi-asserted-by": "publisher", "name": "Region of Southern Denmark" } ], "indexed": { "date-parts": [ [ 2024, 8, 13 ] ], "date-time": "2024-08-13T04:40:05Z", "timestamp": 1723524005614 }, "is-referenced-by-count": 0, "issue": "9", "issued": { "date-parts": [ [ 2024, 9 ] ] }, "journal-issue": { "issue": "9", "published-print": { "date-parts": [ [ 2024, 9 ] ] } }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 9, 1 ] ], "date-time": "2024-09-01T00:00:00Z", "timestamp": 1725148800000 } }, { "URL": "https://www.elsevier.com/legal/tdmrep-license", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 9, 1 ] ], "date-time": "2024-09-01T00:00:00Z", "timestamp": 1725148800000 } }, { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 7, 31 ] ], "date-time": "2024-07-31T00:00:00Z", "timestamp": 1722384000000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S1876034124002466?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S1876034124002466?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "102512", "prefix": "10.1016", "published": { "date-parts": [ [ 2024, 9 ] ] }, "published-print": { "date-parts": [ [ 2024, 9 ] ] }, "publisher": "Elsevier BV", "reference": [ { "DOI": "10.1016/j.jiph.2023.11.029", "article-title": "Real world effectiveness of sotrovimab in preventing COVID-19–related hospitalisation or death in patients infected with Omicron BA.2", "author": "Behzad", "doi-asserted-by": "crossref", "first-page": "315", "issue": "2", "journal-title": "J Infect Public Health", "key": "10.1016/j.jiph.2024.102512_bib1", "volume": "17", "year": "2024" }, { "DOI": "10.1007/s15010-023-02098-5", "article-title": "Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review", "author": "Drysdale", "doi-asserted-by": "crossref", "first-page": "1", "issue": "1", "journal-title": "Infection", "key": "10.1016/j.jiph.2024.102512_bib2", "volume": "52", "year": "2024" }, { "DOI": "10.1016/j.ebiom.2022.104158", "article-title": "Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies", "author": "Wilhelm", "doi-asserted-by": "crossref", "journal-title": "eBioMedicine", "key": "10.1016/j.jiph.2024.102512_bib3", "volume": "82", "year": "2022" }, { "DOI": "10.1038/s41586-022-04856-1", "article-title": "Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2", "author": "Uraki", "doi-asserted-by": "crossref", "first-page": "119", "issue": "7917", "journal-title": "Nature", "key": "10.1016/j.jiph.2024.102512_bib4", "volume": "607", "year": "2022" }, { "DOI": "10.1016/j.heliyon.2023.e16664", "article-title": "Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model", "author": "Hérate", "doi-asserted-by": "crossref", "issue": "6", "journal-title": "Heliyon", "key": "10.1016/j.jiph.2024.102512_bib5", "volume": "9", "year": "2023" }, { "DOI": "10.1016/j.antiviral.2023.105638", "article-title": "Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model", "author": "Driouich", "doi-asserted-by": "crossref", "journal-title": "Antivir Res", "key": "10.1016/j.jiph.2024.102512_bib6", "volume": "215", "year": "2023" }, { "key": "10.1016/j.jiph.2024.102512_bib7", "unstructured": "Zhang A, Stacey HD, D’Agostino MR, Tugg Y, Marzok A, Miller MS. Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nat Rev Immunol; 2022 [Internet] [cited 2023 Sep 13]; Available from: 〈https://www.nature.com/articles/s41577-022-00813-1〉." }, { "key": "10.1016/j.jiph.2024.102512_bib8", "unstructured": "Therapeutics and COVID-19: living guideline, 16 September 2022. Geneva: World Health Organization; 2022 (WHO/2019-nCoV/therapeutics/2022.5). Available from: https://iris.who.int/bitstream/handle/10665/362843/WHO-2019-nCoV-therapeutics-2022.5-eng.pdf." }, { "DOI": "10.1038/s41467-023-40204-1", "article-title": "Monoclonal antibody levels and protection from COVID-19", "author": "Stadler", "doi-asserted-by": "crossref", "first-page": "4545", "issue": "1", "journal-title": "Nat Commun", "key": "10.1016/j.jiph.2024.102512_bib9", "volume": "14", "year": "2023" }, { "DOI": "10.1126/scitranslmed.ado2817", "article-title": "AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults", "author": "Cai", "doi-asserted-by": "crossref", "issue": "753", "journal-title": "Sci Transl Med", "key": "10.1016/j.jiph.2024.102512_bib10", "volume": "16", "year": "2024" }, { "key": "10.1016/j.jiph.2024.102512_bib11", "unstructured": "SUPERNOVA Phase I.I.I. trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population [Internet]. 2024 [cited 2024 Jul 8]. Available from: 〈https://www.astrazeneca.com/media-centre/press-releases/2024/supernova-trial-met-covid-19-prevention-endpoint.html〉." }, { "key": "10.1016/j.jiph.2024.102512_bib12", "unstructured": "F.D.A. (Food and Drug Administration). Fact sheet for patients, parents, and caregivers Emergency Use Authorization (EUA) of PEMGARDA (pemivibart) for coronavirus disease 2019 (COVID-19) [Internet]. [cited 2024 Jul 15]. Available from: 〈https://www.fda.gov/media/177069/download〉." } ], "reference-count": 12, "references-count": 12, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S1876034124002466" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "volume": "17" }